BEDFORD, Mass.--(BUSINESS WIRE)--Jun. 30, 2015--
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company
focused on the development and commercialization of innovative therapies
for diseases and conditions of the eye, today announced that Brad Smith,
Chief Financial Officer, will present a corporate overview at the Cantor
Fitzgerald Inaugural Healthcare Conference on Wednesday, July 8, 2015 at
9:00 a.m. EDT at the Le Parker Meridien Hotel in New York City.
Also at the conference, Scott Corning, Vice President, Sales and
Marketing, will participate in a panel discussion entitled, “Emerging
Trends in Ophthalmology: Innovative Products, FDA and the Evolving
Landscape,” at 1:00 p.m. EDT.
A live audio webcast of the corporate presentation can be accessed
through the Calendar of Events section of the Company's website at investors.ocutx.com.
A replay of the webcast will be available on the Company's website for
two weeks following the presentation.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the
development and commercialization of innovative therapies for diseases
and conditions of the eye using its proprietary hydrogel platform
technology. Ocular Therapeutix's lead product candidates are in Phase 3
clinical development for post-surgical ocular inflammation and pain and
allergic conjunctivitis, and Phase 2 clinical development for glaucoma,
and inflammatory dry eye disease. The Company is also evaluating
sustained-release injectable anti-VEGF drug depots for back-of-the-eye
diseases. Ocular Therapeutix's first product, ReSure®
Sealant, is FDA-approved to seal corneal incisions following cataract
View source version on businesswire.com: http://www.businesswire.com/news/home/20150630005249/en/
Source: Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc.
McClellan on behalf of Ocular Therapeutix
Vice President of Sales and Marketing